Citius Oncology, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $78.3M
- Price
- $0.842
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.06%
- Volume
- 37.2K
About
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
Quick stats
Shares outstanding93.0M
Computed float26.9M
Float / shares28.9%
Cash runway (months)15
Key info
SectorHealthcare
IndustryMedical - Pharmaceuticals
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001851484
AI Summary
AI-generated1/13
minorneutralother
Citius Pharmaceuticals to Participate in September 2026 Investor Conferences
Citius Pharmaceuticals Chairman and CEO Leonard Mazur will present and host one-on-one investor meetings at two September conferences in New York City: the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference (September 9) and the H.C. Wainwright 28th Annual Global Investment Conference (September 15).
Presentations will cover the ongoing commercialization of LYMPHIR (denileukin diftitox-cxdl) by majority-owned subsidiary Citius Oncology (Nasdaq: CTOR), plus the late-stage pipeline including Mino-Lok and Halo-Lido.
Citius Oncology launched LYMPHIR in December 2025 for relapsed or refractory Stage I-III CTCL, and management estimates the initial market exceeds $400 million. Citius Pharma owns approximately 62% of Citius Oncology.